Scandella D - Search Results

1

The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.

Saenko EL, Scandella D. Saenko EL, et al. Among authors: scandella d. J Biol Chem. 1997 Jul 18;272(29):18007-14. doi: 10.1074/jbc.272.29.18007. J Biol Chem. 1997. PMID: 9218428 Free article.

2

In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.

Scandella DH, Nakai H, Felch M, Mondorf W, Scharrer I, Hoyer LW, Saenko EL. Scandella DH, et al. Thromb Res. 2001 Mar 1;101(5):377-85. doi: 10.1016/s0049-3848(00)00418-7. Thromb Res. 2001. PMID: 11297754

3

A role for the C2 domain of factor VIII in binding to von Willebrand factor.

Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. Saenko EL, et al. Among authors: scandella d. J Biol Chem. 1994 Apr 15;269(15):11601-5. J Biol Chem. 1994. PMID: 7512568 Free article.

4

Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.

Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW, Scandella D, Lollar P. Healey JF, et al. Among authors: scandella d. J Biol Chem. 1995 Jun 16;270(24):14505-9. doi: 10.1074/jbc.270.24.14505. J Biol Chem. 1995. PMID: 7540171 Free article.

5

Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.

Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Scandella D, et al. Blood. 1995 Sep 1;86(5):1811-9. Blood. 1995. PMID: 7544643 Free article.

6

A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor.

Saenko EL, Scandella D. Saenko EL, et al. Among authors: scandella d. J Biol Chem. 1995 Jun 9;270(23):13826-33. doi: 10.1074/jbc.270.23.13826. J Biol Chem. 1995. PMID: 7775440 Free article.

7

Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.

Saenko EL, Shima M, Gilbert GE, Scandella D. Saenko EL, et al. Among authors: scandella d. J Biol Chem. 1996 Nov 1;271(44):27424-31. doi: 10.1074/jbc.271.44.27424. J Biol Chem. 1996. PMID: 8910322 Free article.

8

The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, Hurst D, Bray G, Scandella D. Prescott R, et al. Among authors: scandella d. Blood. 1997 May 15;89(10):3663-71. Blood. 1997. PMID: 9160671 Free article.

9

Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors.

Sawamoto Y, Prescott R, Zhong D, Saenko EL, Mauser-Bunschoten E, Peerlinck K, van den Berg M, Scandella D. Sawamoto Y, et al. Among authors: scandella d. Thromb Haemost. 1998 Jan;79(1):62-8. Thromb Haemost. 1998. PMID: 9459325

10

Some human inhibitor antibodies interfere with factor VIII binding to factor IX.

Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Zhong D, et al. Among authors: scandella d. Blood. 1998 Jul 1;92(1):136-42. Blood. 1998. PMID: 9639509 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters